Novartis U.S. to pay $185M marketing fine

Switzerland's Novartis said its U.S. subsidiary struck a plea agreement with U.S. investigators to resolve criminal allegations regarding the company's promotion of the epilepsy drug Trileptal, agreeing to pay a $185 million fine. Report